74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
AxoGen Inc
Open
SectorHealthcare
16.69 -5.28
Overview
Share price change
24h
Min
16.2
Max
17.59
Income | 2.3M 450K |
|---|---|
Sales | 761K 49M |
EPS | 0.07 |
Profit margin | 0.911 |
Employees | 451 |
EBITDA | 2.2M 4.2M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +46.98% upside |
Next Earnings | 1 May 2025 |
|---|
Market Cap | 28M 820M |
|---|---|
Previous open | 21.97 |
Previous close | 16.69 |
News Sentiment
By Acuity
76%
24%
361 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
AxoGen Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
AxoGen Inc Forecast
Price Target
By TipRanks
46.98% upside
12 Months Forecast
Average 26 USD 46.98%
High 30 USD
Low 24 USD
Based on 6 Wall Street analysts offering 12 month price targets forAxoGen Inc - Dist in the last 3 months.
Sentiment
By Acuity
361 / 386 Healthcare
News Sentiment
Very Strong Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About AxoGen Inc
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.
